NYSE:GSK - GlaxoSmithKline Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 14
  • Breakdown:
  • 3 Sell Ratings
  • 4 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$40.15
▼ -0.08 (-0.20%)
1 month | 3 months | 12 months
Get New GlaxoSmithKline Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GSK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GSK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 14 analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $40.15.

Hold

The current consensus among 14 polled investment analysts is to hold stock in GlaxoSmithKline. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 2 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 3 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 3 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 3 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 3 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/11/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
i
6/2/2021Baader BankReiterated RatingBuyLow
i
5/11/2021UBS GroupReiterated RatingNeutralLow
i
4/30/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
i
4/20/2021Morgan StanleyReiterated RatingEqual WeightLow
i
4/20/2021UBS GroupReiterated RatingNeutralLow
i
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market PerformN/A
i
Rating by G. Porges at SVB Leerink LLC
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by G. Porges at SVB Leerink LLC
2/12/2021Morgan StanleyReiterated RatingEqual WeightLow
i
2/11/2021Berenberg BankReiterated RatingBuyLow
i
2/9/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
2/8/2021UBS GroupReiterated RatingNeutralLow
i
2/5/2021BarclaysReiterated RatingUnderweightLow
i
2/3/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
i
1/20/2021UBS GroupReiterated RatingNeutralLow
i
1/20/2021Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
i
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
i
12/16/2020DZ BankReiterated RatingBuyLow
i
12/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
12/3/2020UBS GroupDowngradeBuy ➝ NeutralLow
i
11/13/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
i
11/2/2020Liberum CapitalUpgradeHold ➝ BuyLow
i
10/30/2020BarclaysReiterated RatingUnderweightLow
i
10/21/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/12/2020UBS GroupReiterated RatingBuyLow
i
10/9/2020Morgan StanleyReiterated RatingUnderweightLow
i
10/5/2020Credit Suisse GroupReiterated RatingNeutralLow
i
9/29/2020Berenberg BankInitiated CoverageBuyLow
i
9/23/2020Oddo BhfUpgradeNeutral ➝ BuyMedium
i
9/18/2020Societe GeneraleReiterated RatingBuyLow
i
9/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
i
9/1/2020AlphaValueUpgradeBuyMedium
i
9/1/2020Morgan StanleyReiterated RatingUnderweightMedium
i
8/12/2020UBS GroupReiterated RatingBuyLow
i
5/14/2020UBS GroupReiterated RatingBuyLow
i
5/5/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
4/30/2020BarclaysReiterated RatingUnderweightLow
i
2/12/2020Shore CapitalDowngradeHold ➝ SellLow
i
1/16/2020BarclaysDowngradeEqual Weight ➝ UnderweightLow
i
12/2/2019SVB LeerinkInitiated CoverageOutperformLow
i
Rating by G. Porges at SVB Leerink LLC
11/27/2019UBS GroupUpgradeNeutral ➝ BuyN/A
i
11/21/2019UBS GroupUpgradeNeutral ➝ BuyLow
i
10/16/2019New Street ResearchUpgradeReduce ➝ HoldLow
i
10/11/2019Cantor FitzgeraldUpgradeHold ➝ BuyMedium
i
9/3/2019Societe GeneraleUpgradeSell ➝ BuyLow
i
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
i
8/13/2019JPMorgan Chase & Co.Reiterated RatingNeutral ➝ NeutralLow
i
6/17/2019Morgan StanleyReiterated RatingUnderweight ➝ UnderweightLow
i
6/10/2019CowenReiterated RatingHold$45.00Low
i
3/8/2019Shore CapitalDowngradeBuy ➝ HoldLow
i
2/22/2019UBS GroupDowngradeBuy ➝ NeutralLow
i
1/14/2019Exane BNP ParibasDowngradeOutperform ➝ NeutralMedium
i
1/14/2019BNP ParibasDowngradeOutperform ➝ NeutralMedium
i
12/14/2018Morgan StanleyInitiated CoverageUnderweightLow
i
12/13/2018SunTrust BanksInitiated CoverageHold$38.00Low
i
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$45.00Low
i
12/6/2018BarclaysReiterated RatingOverweight ➝ Equal WeightMedium
i
12/4/2018CfraReiterated RatingHoldMedium
i
Rating by Wan Nurhayati at Cfra
12/4/2018BarclaysDowngradeOverweight ➝ Equal Weight$36.95Low
i
12/3/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/29/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
10/23/2018Wolfe ResearchInitiated CoverageMarket PerformMedium
i
10/10/2018The Goldman Sachs GroupReiterated RatingBuyLow
i
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
i
9/25/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
8/30/2018Liberum CapitalDowngradeBuy ➝ HoldLow
i
8/20/2018ArgusBoost Price TargetBuy ➝ Buy$45.00 ➝ $47.00Low
i
8/1/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
i
7/27/2018Shore CapitalUpgradeHold ➝ BuyLow
i
7/25/2018Bank of AmericaSet Price TargetHold$40.00Medium
i
7/20/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
6/14/2018DZ BankReiterated RatingBuyLow
i
4/9/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
i
4/4/2018BNP ParibasUpgradeNeutral ➝ OutperformMedium
i
3/28/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralMedium
i
3/22/2018Morgan StanleyUpgradeUnderweight ➝ Equal WeightMedium
i
2/15/2018CowenReiterated RatingHold$40.00Low
i
Rating by Steve Scala at Cowen Inc
2/9/2018Kepler Capital MarketsUpgradeReduce ➝ HoldLow
i
2/5/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
i
1/29/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
1/16/2018BarclaysUpgradeEqual Weight ➝ OverweightLow
i
1/15/2018UBS GroupReiterated RatingBuyMedium
i
Rating by Michael Leuchten at UBS Group AG
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
12/11/2017CowenSet Price TargetHold$38.00Low
i
Rating by Steve Scala at Cowen Inc
11/30/2017ArgusLower Price TargetBuy$40.00Low
i
11/27/2017UBS GroupUpgradeNeutral ➝ Buy$35.04 ➝ $35.85Low
i
11/6/2017InvestecDowngradeBuy ➝ HoldN/A
i
10/26/2017Bank of AmericaDowngradeBuy ➝ NeutralN/A
i
Rating by Graham Parry at Bank of America Co.
10/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
10/18/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
9/21/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
9/14/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
9/8/2017Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
i
8/31/2017ArgusReiterated RatingBuy$50.00Low
i
7/27/2017CitigroupReiterated RatingNeutralLow
i
7/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
7/13/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
7/5/2017CitigroupDowngradeBuy ➝ NeutralMedium
i
6/16/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
5/31/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
5/26/2017Berenberg BankUpgradeHold ➝ BuyLow
i
4/25/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
4/6/2017BNP ParibasLower Price Target$37.00Low
i
4/5/2017Exane BNP ParibasUpgradeUnderperform ➝ NeutralLow
i
4/5/2017BNP ParibasUpgradeUnderperform ➝ Neutral$45.58 ➝ $37.20Low
i
4/5/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
i
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLow
i
3/9/2017Kepler Capital MarketsInitiated CoverageReduce ➝ ReduceLow
i
3/7/2017BarclaysInitiated CoverageEqual WeightN/A
i
2/19/2017Jefferies Financial GroupReiterated RatingBuyN/A
i
2/15/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
2/9/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutralN/A
i
2/7/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
1/30/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
12/27/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
12/21/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
12/20/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
12/1/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
11/7/2016CitigroupReiterated RatingBuyN/A
i
10/27/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
i
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/A
i
10/25/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
10/20/2016InvestecInitiated CoverageBuyN/A
i
10/19/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
9/23/2016CitigroupReiterated RatingBuyN/A
i
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/A
i
9/22/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
9/20/2016Bank of AmericaReiterated RatingBuy$50.00N/A
i
9/16/2016Beaufort SecuritiesReiterated RatingBuyN/A
i
9/16/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
9/14/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
9/13/2016BNP ParibasDowngradeNeutral ➝ UnderperformN/A
i
8/17/2016Shore CapitalReiterated RatingHoldN/A
i
8/12/2016ArgusBoost Price TargetBuy$48.00 ➝ $50.00N/A
i
8/11/2016Shore CapitalReiterated RatingHoldN/A
i
8/10/2016CitigroupReiterated RatingBuyN/A
i
8/2/2016Beaufort SecuritiesReiterated RatingBuyN/A
i
7/31/2016BNP ParibasReiterated RatingNeutralN/A
i
7/28/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
7/27/2016Shore CapitalReiterated RatingHoldN/A
i
7/27/2016CitigroupReiterated RatingBuyN/A
i
7/25/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
i
7/19/2016Shore CapitalReiterated RatingHoldN/A
i
7/14/2016Jefferies Financial GroupUpgradeHold ➝ BuyN/A
i
7/1/2016CitigroupUpgradeNeutral ➝ BuyN/A
i
6/27/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
i
6/23/2016CitigroupReiterated RatingBuyN/A
i
6/22/2016Bank of AmericaReiterated RatingBuy$48.00N/A
i
6/21/2016Beaufort SecuritiesReiterated RatingBuyN/A
i
6/21/2016Shore CapitalReiterated RatingHoldN/A
i
(Data available from 6/14/2016 forward)
GlaxoSmithKline logo
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More

Today's Range

Now: $40.15
$39.97
$40.30

50 Day Range

MA: $38.10
$36.02
$40.23

52 Week Range

Now: $40.15
$33.26
$42.40

Volume

2,873,700 shs

Average Volume

5,380,658 shs

Market Capitalization

$108.11 billion

P/E Ratio

14.71

Dividend Yield

5.18%

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of GlaxoSmithKline?

The following Wall Street sell-side analysts have issued reports on GlaxoSmithKline in the last twelve months: AlphaValue, Baader Bank, Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, DZ Bank AG, JPMorgan Chase & Co., Liberum Capital, Morgan Stanley, Oddo Bhf, Societe Generale, SVB Leerink LLC, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GSK.

What is the current price target for GlaxoSmithKline?

0 Wall Street analysts have set twelve-month price targets for GlaxoSmithKline in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for GlaxoSmithKline in the next year.
View the latest price targets for GSK.

What is the current consensus analyst rating for GlaxoSmithKline?

GlaxoSmithKline currently has 3 sell ratings, 4 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GSK, but not buy more shares or sell existing shares.
View the latest ratings for GSK.

What other companies compete with GlaxoSmithKline?

How do I contact GlaxoSmithKline's investor relations team?

GlaxoSmithKline's physical mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company's listed phone number is 44-20-8047-5000 and its investor relations email address is [email protected] The official website for GlaxoSmithKline is www.gsk.com.